Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Berberine on Incretin Secretion in Healthy Men
NCT05947370Phase 1Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of berberine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Serum Glucagon-Like Peptide-1 at 4 hours, Serum Glucose-Dependent Insulinotropic Polypeptide at 4 hours and 1 more. Started Oct 2022; status: completed.
02
Drugs
berberine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05947370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947370.